Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SAFC Pharma, a focus area within SAFC, a member of the Sigma-Aldrich Group, has commissioned a new suite at its St Louis campus that will produce high-potency active pharmaceutical ingredient conjugates to support oncology drug development.
Subscribe to our email newsletter
The 600sqft suite will enable the conjugation of high-potency active pharmaceutical ingredients (HPAPIs) to a variety of targeted delivery molecules, including monoclonal antibodies. In addition, the new facility can accommodate early-stage clinical supplies and can handle multi-kilogram quantities, with the capability to expand production up to commercial scale, the company said.
Dave Feldker, SAFC Pharma’s US vice president, said: “Bioconjugates represent the next generation of smart munitions in healthcare’s anticancer arsenal. Due to our significant breadth of chemistry, containment engineering and biologics capabilities, SAFC Pharma is well-positioned as the leading player in this exciting niche.
“The HPAPI market has grown at a high double-digit pace; the number of customers we have has more than doubled over the past three years, with particular demand growth for biologic-HPAPI conjugates for oncology drugs. Dozens of products are currently in clinical trials, and this new facility underlines SAFC’s intent to support growth in this niche, strengthening our position as the leading pipeline partner for the pharmaceutical and biopharmaceutical industry.”